ASH 2019 | IGVL gene usage explains distinct presentation in IgM AL amyloidosis
IgM-associated light chain (AL) amyloidosis accounts is a rare form of amyloidosis. Patients with IgM AL amyloidosis have a distinct clinical presentation and frequency of organ involvement compared with non-IgM amyloidosis patients. Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, discusses a study investigating the usage of immunoglobulin light chain variable region (IGVL) gene in patients with IgM versus non-IgM amyloidosis. Dr Sidana reveals that two main subtypes of IgM amyloidosis were identified, and treatment should be directed at the underlying clonal disease. This was the first study, to the author’s knowledge, to report IGVL gene usage differences between IgM and non-IgM amyloidosis. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
